Stocktoria
SELLAS Life Sciences Group, Inc. SLS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2008-03-12
SELLAS Life Sciences Group, Inc. statistics & valuation
Market cap$2.3B
P / B32.5×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | — | — | -4195.0% | -332.8% |
| Net margin | — | — | — | -4130.1% | -272.4% |
| Return on assets | -34.3% | -158.9% | -600.4% | -197.2% | -78.8% |
| Return on equity | -37.9% | -326.3% | 468.2% | -851.4% | -101.7% |
| Current ratio | 10.72 | 1.72 | 0.23 | 1.14 | 4.63 |
| Revenue growth | — | — | -100.0% | -86.8% | 300.0% |
Source: SEC EDGAR filings · CIK 0001390478 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.